Nutrient Partitioning

Why Modern Weight Loss Drugs Aren’t Just About “Eating Less”

Every so often, the popular press and medical world get worked up about a new family of weight loss drugs—recently, it’s been the GLP-1 agonists like Wegovy and Ozempic. The dominant narrative is this: these drugs quiet cravings by acting on the brain, squelching “food noise,” and helping you eat less. The implication is that obesity, at root, is about eating too much. Suppress your appetite, force yourself to eat less, and—job done—you’ll lose weight.

I’ll be clear: I don’t accept the conventional calorie-in, calorie-out explanation as the primary driver of why people get fat. I don’t want to ignore basic physics, but this lens misses crucial nuances of human physiology and, frankly, common sense.

The Real Question: Why Do We Get Fat?

Let’s revisit the ‘why do we get fat?’ question. The classic “energy balance” model says you gain weight when you eat more than you burn—simple as an accounting equation. But this theory stumbles over a hard-to-ignore observation: plenty of people become obese while eating no more (and often less) than their lean peers. I’ve seen countless clients—eating modestly, struggling valiantly—still unable to prevent weight gain or achieve sustainable fat loss.

If it were purely about greed or laziness, none of these folks would succeed on approaches that restore metabolic health without asking them to battle constant hunger.

So what’s going on? The alternative is the “nutrient partitioning” (or “fuel-partitioning”) model, which focuses not on how much you eat, but on what your body does with the nutrients you provide. Some people’s physiology, especially in an environment of high refined-carb intake, seems to favor storing fat rather than burning it for fuel. The critical regulators here are hormonal—mainly insulin, but also the intricate neuroendocrine orchestra involving the central nervous system.

When this partitioning leans too much toward storage, the body traps away energy as fat, and your cells act as if they’re running on empty (even with ample reserves locked up). That’s why someone can be both overweight and still feel ravenous—because, on a cellular level, they’re starving.

GLP-1 Drugs Through the Lens of Nutrient Partitioning

If you view drugs like Tirzepatide through the lens of nutrient partitioning, things start to make a lot more sense compared to the “it just makes you eat less” dogma.

What these drugs appear to do is unlock stored fat, shifting the balance away from storage and toward oxidation (burning fat for energy). When your body is genuinely using its own fat as fuel, two things happen:

1. You’re being fed from within.
   If you liberate fat from storage, that fat isn’t just disappearing; your body is using it for fuel. Put simply: you may “eat less” with your mouth, but metabolically, you’re still eating plenty because you’re burning what you previously stored. That means less hunger, not because your brain has been tricked, but because your body genuinely isn’t running a large deficit.

2. Fat loss becomes tangible and explainable—even for the calorie counters.
   Let’s appease the calorie accountants for a moment. Lose 2 lbs of fat in a week, and you’ve just contributed about 7,000 “calories” (I use this term reluctantly—the calorie model, while neat for textbooks, ignores a lot of biochemistry, but I mention it for context) into your energy pool, drawn straight from your own fat stores. For all practical purposes, that’s like eating more than a stick of butter per day—no wonder you’re not as hungry.

So when people tell me, “I’m not as hungry on this medication,” or “I can fast for longer,” this is what’s happening. They’re no longer dependent solely on what’s coming in through the mouth—internal reserves are finally accessible.

What Does the Science Show?

A recent study looked at the effects of Tirzepatide (the active GLP-1/GIP analog in Mounjaro) in both mice and humans. Here’s the gist, stripped of fluff:

• In semi-starved mice (calories matched between drug and placebo groups), those treated with Tirzepatide lost significantly more fat. Not by eating less (they all ate the same), but by burning more fat for energy—an effect demonstrated by a lower respiratory exchange ratio (RER, a technical marker showing which fuel—carbs or fat—is being burned).

• Crucially, the treated mice didn’t experience the usual “starvation response.” Calorie-restricted controls slowed their metabolism (a built-in survival feature); the GLP-1 group didn’t. They kept burning energy, drawing down fat stores instead of crashing into lethargy and endless hunger.

• Among humans, the anti-hunger, pro-fat-burning effect was also seen, though the experiment’s design made it harder to tease out some details (like how energy expenditure changed during the most rapid weight-loss phase).

The upshot? These drugs support the fuel-partitioning model: they free stored fat, leading to less hunger, more fat oxidation, and less of the metabolic slowdown that usually sabotages dieters.

The Metabolic Perspective: A State of Internal Feeding

This is the best way I can put it for anyone who’s struggled on restrictive diets or seen their patients do the same:

• As long as your body is trapping fat away and not burning it, you’re fighting an uphill battle against biology.

• But when you can access stored fat, your body “feeds” itself. The result is a calm, natural reduction in appetite—not a forced one—and a willingness to keep moving, thinking, and living well.

• Once those fat stores run down to a new set point, hunger tends to return—your body wants homeostasis, not eternal weight loss.

Why Does This Matter?

If we’re going to make headway in tackling obesity—clinically, personally, and as a society—we need to understand that it’s not about blaming the individual for “eating too much.” The core problem, and the main therapeutic target, is how our bodies partition fuel and regulate fat storage versus oxidation. That’s orchestrated by hormones, macronutrient composition, and complex neuroendocrine signaling.

So, whether you’re using medication, a ketogenic or carnivore approach, or metabolic interventions of other kinds, remember: successful fat loss is about making stored energy accessible. When you’re genuinely burning your own fat for fuel, you’re no longer starving on the inside, and your hunger decreases naturally.

And yes—by the textbooks, if you’re losing several pounds of fat a month, you are, in effect, eating hundreds (or thousands) of calories a day straight from your own adipose tissue, calorie theory or not. I mention the numbers for completeness, but my real interest lies in the physiology that makes sustainable fat loss possible.

Summary:

• True weight regulation happens not by brute-force cutting of calories, but by shifting the body’s priority from fat storage to fat burning.

• GLP-1 drugs (and by extension, dietary strategies like keto/carnivore) appear most effective when they shift this metabolic balance, allowing the body to “feed itself” from within.

• Lasting fat loss demands physiological—not just psychological—access to your own energy reserves.

That’s the real story behind nutrient partitioning. Until next time, keep questioning the simple narratives, and don’t be ashamed to demand that weight loss interventions actually make sense on a metabolic, not just mathematical, level.

1. Primary Reference for the Tirzepatide Pair-Feeding Study (Fuel Partitioning, RER, Energy Expenditure)

• Citation: The recent detailed lay analysis and direct links to the study methodology are well summarised here, which also includes references to the primary peer-reviewed publication:

  • Gary Taubes: Why Do We Lose Weight on GLP-1 Drugs? Uncertainty Principles Substack, April 24, 2025
    This essay walks through the experimental design—pair-feeding in mice, free-feeding in humans, the use of indirect calorimetry, respiratory exchange ratio (RER), and energy expenditure findings. It also explains the fat-oxidation findings in both species, and references the Cell Metabolism paper at the heart of the original article.

---

2. Peer-Reviewed Studies: GLP-1/GIP Agonists, Fat Oxidation, and Obesity

• **Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects with Type 2 Diabetes
  ResearchGate summary and PDF link (with references to original studies on fat/energy partitioning)

• Optimized GIP analogs promote body weight lowering in mice via GIPR agonism (fuel partitioning mechanisms)

  • ScienceDirect: Molecular Metabolism, 2019

• Oral Abstracts – 2024 – Obesity (GLP-1 receptor agonist gene therapy, fat oxidation in DIO mice)

  • Wiley Online Library

---

Key Findings from These References:

• Pair-feeding studies demonstrated that Tirzepatide-treated mice lost more weight and had higher fat oxidation (lower RER) vs. calorie-matched controls, with less or no drop in energy expenditure.

• Human studies noted increased fat oxidation (reduced RER) on GLP-1/GIP analogues, though energy expenditure effects were less robust (and measured after weight plateau).

• The data supports a fuel-partitioning metabolic model where unlocking fat stores reduces hunger and supports ongoing energy needs—not just appetite “suppression.”

---

Additional Mechanistic and Review Material:

• GLP-1 Agonism Stimulates Brown Adipose Tissue Thermogenesis and Fat Browning
  GLP-1, UCP-1, AMPK pathways link – mechanistic review, ResearchGate